Integra Therapeutics closes round of financing for €4.5 million

Cuatrecasas advised Invivo Capital, Advent Biotechnology and Takeda Ventures on the round of financing in Integra Therapeutics.

Integra Therapeutics closes round of financing for €4.5 million
December 13, 2021

Cuatrecasas advised Invivo Capital, Advent Biotechnology and Takeda Ventures on the round of financing in Integra Therapeutics. At closure of the transaction, the spin-off of Universitat Pompeu Fabra (UPF) will receive seed funding of €4.5 million from the mentioned investors.

The startup Integra Therapeutics, founded in 2020 in Barcelona, develops a state-of-the-art gene editing platform that will make advanced therapies safer and more effective. The round of capital will enable the startup to complete the prototype for its new gene editing technology platform, carry out preclinical validation with in vivo and ex vivo models, and manage its patent portfolio between 2022 and 2023. Later, the company expects to open a series A round to seek regulatory approval and carry out clinical trials with patients.

"We are very satisfied that this seed round is funded by a syndicate of international investors, yet another example of the opportunity offered by technology transfer and the competitiveness of the biotechnological ecosystem in Spain,” says Luis Pareras, Invivo Capital partner.

The team handling this transaction was made up of lawyers from the firm’s Madrid Corporate and Commercial Practice, Diana Rivera, Amador Rodríguez and Julio Otero.

December 13, 2021